^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Hansizhuang (serplulimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
Excerpt:
Shanghai Henlius Biotech, Inc...announced...HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs containing fluorouracil and platinum for the first-line treatment of patients with PD-L1 positive unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC), has been approved by the National Medical Products Administration (the "NMPA"), providing a new treatment option for patients with ESCC.
Source:
Title:
A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy
Excerpt:
...Patients whose tumour specimens are tested positive for PD-L1 expression (CPS ≥ 1)....
Trial ID:
Source:
Title:
Efficacy and safety evaluation of HLX10 (a recombinant humanized anti-PD-1 monoclonal antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy: A single-arm, open-label, phase 2 study.
Published date:
05/19/2021
Excerpt:
143 eligible patients aged between 18 and 75, with histologically or cytologically diagnosed cervical cancer and positive PD-L1 expression....demonstrated a manageable safety profile and encouraging efficacy (ORR 52.4%) of HLX10 plus albumin-bound paclitaxel in advanced cervical cancer patients who have progressive disease or intolerable toxicity to first-line standard chemotherapy…
Secondary therapy:
albumin-bound paclitaxel
Trial ID:
